{"commentary":{"count":17,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":8,"youtube":5,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03631784\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"KEYNOTE-799","nct_id":"NCT03631784","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-799-nct03631784. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"KEYNOTE-799","arms":[{"description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.","label":"Cohort A","type":"EXPERIMENTAL"},{"description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.","label":"Cohort B","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-03-19","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":216,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab 200 mg","type":"DRUG"},{"name":"Paclitaxel 45 mg/m^2","type":"DRUG"},{"name":"Carboplatin AUC6","type":"DRUG"},{"name":"Cisplatin 75 mg/m^2","type":"DRUG"},{"name":"Pemetrexed 500 mg/m^2","type":"DRUG"},{"name":"Thoracic Radiation Therapy (TRT)","type":"RADIATION"},{"name":"Paclitaxel 200 mg/m^2","type":"DRUG"},{"name":"Carboplatin AUC2","type":"DRUG"}],"last_update":"2025-03-25","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-10-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis","timeFrame":"Up to approximately 3 years"},{"measure":"Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","timeFrame":"Up to approximately 3 years"}],"references":[{"citation":"Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301. Online ahead of print.","pmid":"34086039","type":"RESULT"}],"start_date":{"date":"2018-10-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)","url":"https://clinicaltrials.gov/study/NCT03631784"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-799-nct03631784"}